Using PET/MR imaging to improve diagnosis of brain diseases
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
This study is testing if using advanced PET/MR imaging with artificial intelligence can help doctors diagnose brain diseases like Alzheimer's and Parkinson's more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2300 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06092125 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to explore the application of domestic PET/MR imaging in diagnosing major neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and malignant brain tumors. The study will utilize artificial intelligence to enhance the accuracy of diagnosis and target localization for these conditions. Participants will undergo PET/MR scans, and the research will involve a significant sample size to ensure robust data collection and analysis. The goal is to improve early diagnosis and treatment options in clinical practice.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with mild cognitive impairment, Alzheimer's disease, Parkinson's disease, epilepsy, or malignant brain tumors who are admitted for inpatient treatment.
Not a fit: Patients who have recently undergone certain treatments or have severe uncontrolled conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of major brain diseases, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for neurological disorders, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines. 2. Patients admitted to our hospital for inpatient treatment. Exclusion Criteria: 1. Patients who have undergone non-invasive/minimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month. 2. Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination. 3. patients with poorly controlled blood sugar and ineffective medication intervention. 4. Patients with absolute contraindications for PET/MR examination. 5. Karnofsky Performance Score (KPS) \<60.
Where this trial is running
Beijing, Beijing Municipality
- Xuanwu hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Jie Lu, Phd — Xuanwu Hospital of Capital Medical University
- Study coordinator: Jie Lu, Phd
- Email: imaginglu@hotmail.com
- Phone: +86 13309824318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.